丙型肝炎病毒复制小分子抑制剂的三联药物协同相互作用
3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.
作者信息
Grünberger Christian, Wyles David L, Kaihara Kelly A, Schooley Robert T
机构信息
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, USA.
出版信息
J Infect Dis. 2008 Jan 1;197(1):42-5. doi: 10.1086/524062.
Abstract
Small molecular inhibitors of hepatitis C virus (HCV) replication provide remarkable potency, but the rapid selection of resistance mutations will require that these agents be used in combination for clinical treatment. Using a model HCV replicon system, we have extended prior in vitro studies of double combinations of candidate small molecular inhibitors to studies evaluating the simultaneous use of 3 agents. This was done in an effort to anticipate conditions that might ultimately be required clinically. We formally demonstrate synergistic antiviral activity with 3-drug combinations in this model, further supporting the concept of clinical investigations of combination therapy for HCV infection.
摘要
丙型肝炎病毒（HCV）复制的小分子抑制剂具有显著的效力，但耐药突变的快速出现意味着这些药物需要联合用于临床治疗。利用一个HCV复制子模型系统，我们将之前对候选小分子抑制剂双重组合的体外研究扩展到了对三种药物同时使用的评估研究。这样做是为了预测临床上最终可能需要的情况。我们在该模型中正式证明了三种药物联合具有协同抗病毒活性，进一步支持了针对HCV感染进行联合治疗临床研究的理念。
相似文献
1
3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.丙型肝炎病毒复制小分子抑制剂的三联药物协同相互作用
J Infect Dis. 2008 Jan 1;197(1):42-5. doi: 10.1086/524062.
2
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.针对多个病毒靶点的丙型肝炎病毒复制小分子抑制剂的协同作用。
J Virol. 2007 Mar;81(6):3005-8. doi: 10.1128/JVI.02083-06. Epub 2006 Dec 20.
3
Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.亲环蛋白抑制剂NIM811与丙型肝炎病毒NS3-4A蛋白酶或NS5B聚合酶抑制剂联合使用可增强抗病毒活性并抑制耐药性的出现。
Antimicrob Agents Chemother. 2008 Sep;52(9):3267-75. doi: 10.1128/AAC.00498-08. Epub 2008 Jun 30.
4
Inhibitory effects of Pycnogenol® on hepatitis C virus replication.碧萝芷对丙型肝炎病毒复制的抑制作用。
Antiviral Res. 2015 Jan;113:93-102. doi: 10.1016/j.antiviral.2014.10.017. Epub 2014 Nov 20.
5
A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.一种基于细胞复制子的表型分析方法，用于确定丙型肝炎病毒临床分离株对NS3/4A蛋白酶抑制剂的敏感性。
Methods Mol Biol. 2013;1030:105-17. doi: 10.1007/978-1-62703-484-5_9.
6
Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.认识直接作用抗病毒药物的类别：优势与劣势
Clin Liver Dis. 2015 Nov;19(4):605-17, v. doi: 10.1016/j.cld.2015.06.002. Epub 2015 Jul 26.
7
Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.寻找协同作用：在复制子系统中使用丙型肝炎病毒 (HCV) 药物确定最佳抗病毒联合治疗方案。
Antiviral Res. 2017 Oct;146:149-152. doi: 10.1016/j.antiviral.2017.09.001. Epub 2017 Sep 4.
8
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.λ干扰素与直接作用抗病毒药物联合使用，能高效抑制丙型肝炎病毒复制。
Antimicrob Agents Chemother. 2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12. Epub 2012 Dec 28.
9
Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.新一代丙型肝炎病毒 NS3/4A 蛋白酶抑制剂格卡瑞韦的抗病毒活性和耐药谱。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01620-17. Print 2018 Jan.
10
Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.建立一个过表达 P-糖蛋白的稳健丙型肝炎病毒复制子细胞系，以促进分析 P-糖蛋白药物转运体对抑制剂抗病毒活性的影响。
Biochem Pharmacol. 2013 Jan 1;85(1):21-8. doi: 10.1016/j.bcp.2012.10.002. Epub 2012 Oct 11.
引用本文的文献
1
Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes.模型研究提示丙型肝炎病毒进入抑制剂与其他类药物之间的协同作用机制。
CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):445-53. doi: 10.1002/psp4.12005. Epub 2015 Jul 6.
2
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.评价 ITX 5061，一种清道夫受体 B1 拮抗剂：耐药性选择和与其他丙型肝炎病毒抗病毒药物联合的活性。
J Infect Dis. 2012 Feb 15;205(4):656-62. doi: 10.1093/infdis/jir802.
3
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.丙型肝炎特异性靶向抗病毒治疗的病毒反应及其对治疗成功的影响。
Can J Gastroenterol. 2010 Jun;24(6):385-90. doi: 10.1155/2010/125435.
4
GSK983: a novel compound with broad-spectrum antiviral activity.
Antiviral Res. 2009 Apr;82(1):1-11. doi: 10.1016/j.antiviral.2008.12.015. Epub 2009 Jan 31.
5
Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.丙型肝炎病毒（HCV）NS4A拮抗剂与HCV蛋白酶和聚合酶抑制剂联合使用的协同作用。
Antimicrob Agents Chemother. 2008 May;52(5):1862-4. doi: 10.1128/AAC.01208-07. Epub 2008 Mar 10.
本文引用的文献
1
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.针对多个病毒靶点的丙型肝炎病毒复制小分子抑制剂的协同作用。
J Virol. 2007 Mar;81(6):3005-8. doi: 10.1128/JVI.02083-06. Epub 2006 Dec 20.
2
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.成人HIV感染的治疗：美国国际艾滋病学会专家组2006年建议
Top HIV Med. 2006 Aug-Sep;14(3):827-43.
3
Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.利巴韦林与α-干扰素联合应用对细胞内丙型肝炎病毒复制的协同抑制作用
J Infect Dis. 2004 Apr 1;189(7):1129-39. doi: 10.1086/382595. Epub 2004 Mar 16.
4
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎病毒感染
N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047.
5
Surprisingly small effect of antiviral treatment in patients with hepatitis C.抗病毒治疗对丙型肝炎患者的效果惊人地小。
Ann Intern Med. 2002 Feb 19;136(4):288-92. doi: 10.7326/0003-4819-136-4-200202190-00008.
6
Effect of alpha interferon on the hepatitis C virus replicon.α干扰素对丙型肝炎病毒复制子的作用。
J Virol. 2001 Sep;75(18):8516-23. doi: 10.1128/jvi.75.18.8516-8523.2001.
7
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.晚期人类免疫缺陷病毒感染患者的发病率和死亡率下降。HIV门诊研究调查人员。
N Engl J Med. 1998 Mar 26;338(13):853-60. doi: 10.1056/NEJM199803263381301.
8
Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C.慢性丙型肝炎患者中丙型肝炎病毒变异体的演变与选择
Virology. 1994 Nov 15;205(1):161-9. doi: 10.1006/viro.1994.1631.
9
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.剂量-效应关系的定量分析：多种药物或酶抑制剂的联合效应
Adv Enzyme Regul. 1984;22:27-55. doi: 10.1016/0065-2571(84)90007-4.
10
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.叠氮胸苷与重组αA干扰素在体外对人类免疫缺陷病毒的协同抑制作用。
Antimicrob Agents Chemother. 1987 Feb;31(2):168-72. doi: 10.1128/AAC.31.2.168.
Zotero 插件